Figure 2
Figure 2. Transgenic mice of sublines E and G differ in their antibody responses to human FVIII. Mice were treated with 8 weekly intravenous doses of human FVIII. Blood for antibody analysis and spleens for the analysis of antibody-secreting cells (ASC) were collected 1 week after the last dose. (A) Titers of anti–human FVIII IgG antibodies were detected by ELISA. Antibody titers were shown for individual mice. Anti-FVIII antibody-secreting cells (ASC) were analyzed by ELISPOT. Results obtained from a representative mouse are shown. Each spot corresponds to 1 ASC. (B) Plasma samples from 3 mice of each subline were analyzed for both titers of anti–human FVIII IgG antibodies by ELISA and FVIII inhibitor titers by Bethesda assay.

Transgenic mice of sublines E and G differ in their antibody responses to human FVIII. Mice were treated with 8 weekly intravenous doses of human FVIII. Blood for antibody analysis and spleens for the analysis of antibody-secreting cells (ASC) were collected 1 week after the last dose. (A) Titers of anti–human FVIII IgG antibodies were detected by ELISA. Antibody titers were shown for individual mice. Anti-FVIII antibody-secreting cells (ASC) were analyzed by ELISPOT. Results obtained from a representative mouse are shown. Each spot corresponds to 1 ASC. (B) Plasma samples from 3 mice of each subline were analyzed for both titers of anti–human FVIII IgG antibodies by ELISA and FVIII inhibitor titers by Bethesda assay.

Close Modal

or Create an Account

Close Modal
Close Modal